FDA's ODAC votes unan­i­mous­ly that fu­ture PI3K in­hibitors should in­clude ran­dom­ized da­ta for blood can­cers

A pan­el of FDA’s out­side ad­vi­sors unan­i­mous­ly vot­ed, with one ab­sten­tion, that fu­ture ap­provals of PI3K in­hibitors should be sup­port­ed by ran­dom­ized da­ta.

The 17 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER